Medicine and Dentistry
Adverse Event
5%
Arm
6%
Bladder
6%
Bladder Cancer
6%
Brachytherapy
13%
Brain Metastasis
5%
Breast Cancer
14%
Cancer
5%
Carcinoma
5%
Cervical Cancer
7%
Chemoradiotherapy
8%
Chemotherapy
13%
Clinical Trial
14%
Computer Assisted Tomography
8%
Conformal Radiotherapy
6%
Contouring
6%
Disease
18%
Disease Free Survival
5%
Distant Metastasis
5%
Drug Megadose
8%
External Beam Radiotherapy
10%
Glioblastoma
6%
Hazard Ratio
10%
Head and Neck Cancer
6%
Intensity Modulated Radiation Therapy
20%
Low Drug Dose
5%
Lung
7%
Lung Cancer
9%
Lymph Node
7%
Magnetic Resonance Imaging
11%
Malignant Neoplasm
19%
Metastatic Carcinoma
7%
Neck
8%
Neoplasm
38%
Non Small Cell Lung Cancer
18%
Oncology
26%
Oropharynx Carcinoma
5%
Oropharynx Squamous Cell Carcinoma
8%
Overall Survival
33%
Pelvis
8%
Positron Emission Tomography
6%
Progression Free Survival
7%
Prostate Cancer
33%
Prostate Specific Antigen
6%
Prostatectomy
5%
Proton Therapy
8%
Quality of Life
9%
Radiation Oncologist
5%
Radiation Oncology
13%
Radiation Therapy
100%
Recurrent Disease
13%
Stereotactic Body Radiation Therapy
19%
Stereotactic Radiosurgery
5%
Surgery
11%
Treatment Planning
13%
Wart Virus
8%
Keyphrases
Adaptive Radiotherapy
7%
Androgen Deprivation Therapy
6%
Bladder Cancer
5%
Brachytherapy
7%
Brain Metastases
6%
Breast Cancer
5%
Cervical Cancer
6%
Chemotherapy
9%
Clinical Outcomes
6%
Clinical Target Volume
6%
Clinical Trials
7%
Computed Tomography
6%
Confidence Interval
13%
Disease-free Survival
5%
Distant Metastasis
6%
Dose Escalation
5%
External Beam Radiotherapy
9%
Glioblastoma
5%
Hazard Ratio
10%
Head-and-neck
6%
Head-and-neck Cancer
7%
High Dose
7%
High Risk
6%
High-risk Human Papillomavirus (HR-HPV)
9%
Hyperthermia
7%
Intensity-modulated Radiation Therapy
12%
Intensity-modulated Radiotherapy
5%
Irradiation
6%
Local Control
9%
Magnetic Resonance Imaging
8%
Multi-institutional
5%
Multivariate Analysis
5%
Non-small Cell Lung Cancer (NSCLC)
14%
NRG Oncology
10%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
12%
Overall Survival
32%
Phase II Trial
7%
Planning Target Volume
5%
Positron Emission Tomography
5%
Progression-free Survival
8%
Prostate
7%
Prostate Cancer
15%
Prostate-specific Antigen
6%
Proton Therapy
6%
Quality Assurance
7%
Quality of Life
6%
Radiation Dose
6%
Radiation Oncologist
6%
Radiation Oncology
13%
Radiation Therapy
49%
Radiation Therapy Oncology Group
13%
Radiotherapy
23%
Stereotactic Body Radiation Therapy
14%
Stereotactic Body Radiotherapy
5%
Stereotactic Radiosurgery
6%
Three-dimensional Conformal Radiotherapy
6%
Treatment Plan
5%
Treatment Planning
7%
Tumor
20%